Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TAS1R3 | Q7RTX0 | 2/20 | 0.71 |
| ▸ | TAS1R1 | Q7RTX1 | 2/20 | 0.71 |
| ▸ | PI4KA | P42356 | 5/20 | 0.48 |
| ▸ | PI4K2B | Q8TCG2 | 5/20 | 0.48 |
| ▸ | PI4K2A | Q9BTU6 | 5/20 | 0.48 |
| ▸ | PI4KB | Q9UBF8 | 5/20 | 0.48 |
| ▸ | ADORA2A | P29274 | 10/20 | 0.45 |
| ▸ | ADORA1 | P30542 | 6/20 | 0.45 |
| ▸ | GMPS | P49915 | 1/20 | 0.43 |
| ▸ | ADORA2B | P29275 | 2/20 | 0.43 |
| ▸ | ADORA3 | P0DMS8 | 2/20 | 0.41 |
| ▸ | SLC28A1 | O00337 | 1/20 | 0.41 |
| ▸ | AHCY | P23526 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26972744 | 0.87 | TAS1R3 (0.59) | TAS1R3TAS1R1PI4KAPI4K2BPI4K2A | |
| SCHEMBL26972747 | 0.86 | TAS1R3 (0.58) | TAS1R3TAS1R1PI4KAPI4K2BPI4K2A | |
| SCHEMBL20277482 | 0.83 | TAS1R3 (1.00) | TAS1R3TAS1R1PI4KAPI4K2BPI4K2A | |
| SCHEMBL20673335 | 0.83 | TAS1R3 (0.81) | TAS1R3TAS1R1PI4KAPI4K2BPI4K2A | |
| SCHEMBL24059938 | 0.83 | TAS1R3 (1.00) | TAS1R3TAS1R1PI4KAPI4K2BPI4K2A | |
| SCHEMBL10294620 | 0.79 | TAS1R3 (0.74) | TAS1R3TAS1R1 | |
| SCHEMBL21031870 | 0.78 | TAS1R3 (0.59) | TAS1R3TAS1R1PI4KAPI4K2BPI4K2A | |
| SCHEMBL14162591 | 0.77 | TAS1R3 (0.55) | TAS1R3TAS1R1PI4KAPI4K2BPI4K2A | |
| SCHEMBL226040 | 0.71 | ADORA2A (0.56) | TAS1R3TAS1R1PI4KAPI4K2BPI4K2A | |
| SCHEMBL8087444 | 0.70 | GMPS (0.53) | TAS1R3TAS1R1PI4KAPI4K2BPI4K2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11857561-B2 | Methods for the use of 5′-adenosine diphosphate ribose (ADPR) | INVIRSA, INC. (US) | 2024-01-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11857561-B2 | Methods for the use of 5′-adenosine diphosphate ribose (ADPR) | ADAR, CD38, PARP1 | TAS1R3 2968/4885TAS1R1 3331/4885PI4KA 2469/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.